[6] Shimin Hu,Zijun Y, Xu-Monette, et al.MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from ...
www.nature.com/scientificreports OPEN received: 04 February 2016 accepted: 25 May 2016 Published: 13 June 2016 A potential panel of six-long non- coding RNA signature to improve survival prediction of diffuse large- B-cell lymphoma Jie Sun*, Liang Cheng*, Hongbo Shi*, Zhaoyue ...
e19075#Background:Orbital diffuse large B-cell lymphoma is a rare entity accounts for less than 1% of all non-Hodgkin lymphoma cases. Large-scale studies describing and evaluating the effect of different type of treatments on survival outcome are lacking.Methods:The National Cancer Database (NCDB...
弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)是一种来源于成熟B细胞的侵袭性肿瘤,是最常见的NHL类型,中老年发病居多,男性略多于女性,病理类型复杂,其临床异质性大,同一种疾病表现不同的预后,那么分型及预后分层评分系统在临床...
et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346, 1937–1947 (2002). 8. Coutinho, R. et al. Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: ...
5. Bataillard EJ, Cheah CY, Maurer MJ, Khurana A, Eyre TA, El-Galaly TC. Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. Blood Adv. 2021;5(9):2426-37. 6. Xue E, Xie H, Leisenring WM, Kimball LE, Goyal S, Chung L,...
thetumor microenvironmentis important to the survival of lymphoma cells via tumor cell–microenviroment cellular interactions[1–3]. One of the most important normal cellular pathways is the nuclear factor-kappaB (NF-κB) pathway. NF-κB transcription factor family members are involved in many physio...
[6] Shimin Hu,Zijun Y, Xu-Monette, et al.MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Conso...
参考来源：‘Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study’，新闻稿。Genentech；2024年4月14日发布。注：本文旨在介绍医药健康研究，不作任何用药依据，具体用药指引，请咨询主治医师。
[6] Shimin Hu,Zijun Y, Xu-Monette, et al.MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program,...